Real-world Gluten Exposure in Patients With Celiac Disease on Gluten-Free Diets, Determined From Gliadin Immunogenic Peptides in Urine and Fecal Samples.

Like Comment
It is not clear how often patients who are on gluten-free diets (GFDs) for treatment celiac disease are still exposed to gluten. We studied levels of gluten immunogenic peptides (GIP) in fecal and urine samples, collected over 4 weeks, from patients with celiac disease following a long-term GFD.We performed a prospective study of 53 adults with celiac disease who had been on a GFD for more than 2 years (median duration, 8 years; interquartile range, 5-12 years) in Argentina. At baseline, symptoms were assessed by the celiac symptom index questionnaire. Patients collected stool each Friday and Saturday and urine samples each Sunday for 4 weeks. We used a commercial ELISA to measure GIP in stool and point-of-care tests to measure GIP in urine samples.Overall, 159 of 420 stool and urine samples (37.9%) were positive for GIP; 88.7% of patients had at least 1 fecal or urine sample that was positive for GIP (median, 3 excretions). On weekends (urine samples), 69.8% of patients excreted GIP at least once, compared with 62.3% during weekdays (stool). The number of patients with a sample that was positive for GIP increased over the 4-week study period (urine samples in week 1 vs week 4, P

Click here to read the full article @ Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following